drugset / Trial / NCT00599638

A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia

NCT00599638

Phase 2 Completed 72 enrolled Pfizer
RandomizedCrossoverTriple-blindTreatment

Summary

Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug. This study will compare the efficacy of pregabalin when administered with an experimental drug PF-00489791, in patients with post-herpetic neuralgia. The efficacy of this combination will be compared to pregabalin alone.

Timeline

Start
2008-04-09
Primary completion
2008-12-16
Completion
2008-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-00489791 Small molecule 10 mg
Subject Pregabalin Small molecule 150 mg